(Q44079530)

29 November 2017

title

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study (English)

1 reference

29 November 2017

Morant R

1

1 reference

29 November 2017

Hsu Schmitz SF

2

1 reference

29 November 2017

Bernhard J

3

1 reference

29 November 2017

Thürlimann B

4

1 reference

29 November 2017

Borner M

5

1 reference

29 November 2017

Wernli M

6

1 reference

29 November 2017

Egli F

7

1 reference

29 November 2017

Forrer P

8

1 reference

29 November 2017

Streit A

9

1 reference

29 November 2017

Jacky E

10

1 reference

29 November 2017

Hanselmann S

11

1 reference

29 November 2017

Bauer J

12

1 reference

29 November 2017

Hering F

13

1 reference

29 November 2017

Schmid HP

14

1 reference

29 November 2017

publication date

1 August 2002

1 reference

European Journal of Cancer

29 November 2017

published in

1 reference

29 November 2017

volume

38

1 reference

29 November 2017

issue

12

1 reference

29 November 2017

page(s)

1626-1632

1 reference

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900145-4

7 January 2021

10.1016/S0959-8049(02)00145-4

Identifiers

DOI

1 reference

29 November 2017

1 reference